香港开启全民检测,中国生物科技服务(8037.HK)旗下全港最大新冠检测机构为香港抗疫作出主要贡献
格隆汇8月28日丨香港政府已公布普及社区检测计划细节及具体安排,计划于9月1日正式开展,为期7天,视进度再延长不超过7天至9月14日。市民明日(29日)早上7时起可在网上预约。详情请浏览链接(https://www.communitytest.gov.hk/)
据悉,香港上市公司中国生物科技服务(8037.HK)正持续不断的扩大新冠检测业务的布局。
2020年上半年,为了满足香港与内地的通关需求,公司取得了英诺特授权的“新冠抗体检测试剂盒”海外分销权,并推出新冠核酸检测(自愿)项目,早期的核酸检测量大致为每日600人。另外,公司成为了华大基因的分销商,获得了向海外销售新冠核酸检测试剂盒的授权。
伴随着香港疫情再次爆发,新冠检测需求激增,公司除了销售新冠核酸检测试剂盒之外,还与国内顶尖检测机构进行合资成立新冠检测实验室。
2020年6月,中国生物科技服务与华大健康香港有限公司及香港前医管局主席、现任全国政协常委胡定旭先生成立了华昇诊断中心(SUNRISE),引进华大基因的火眼实验室,成为香港目前新冠核酸检测规模最大的一家机构,也是香港拥有高检测能力的新冠检测实验室之一。
另外,根据公司在8月18日的公告显示,为提高检测速度,为抗疫保驾护航,公司在香港政府配合下额外设立及经营一间有16个气膜的临时实验室,并在国家检测支援队几百人的大力支持下为香港市民提供新冠检测。额外的实验室每日可进行约10万次单管测试,将使得华昇诊断中心(SUNRISE)由每天的检测量3万人份增至13万人份。
由于香港能够提供新冠核酸检测的公司较少,且中国生物科技服务公司的是香港规模最大的一家机构,公司本身业务又具备优良的精准诊断基因,在市场竞争中,新冠检测业务将使得公司知名度和市场份额都大幅提高。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.